Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
Molnupiravir in COVID-19: A systematic review of literature
AK Singh, A Singh, R Singh, A Misra - Diabetes & Metabolic Syndrome …, 2021 - Elsevier
Background and aims Molnupiravir is a newer oral antiviral drug that has recently been
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients
A Jayk Bernal, MM Gomes da Silva… - … England Journal of …, 2022 - Mass Medical Soc
Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
F Kabinger, C Stiller, J Schmitzová… - Nature structural & …, 2021 - nature.com
Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …
[HTML][HTML] Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets
Abstract The coronavirus disease 2019 (COVID-19) pandemic is having a catastrophic
impact on human health 1. Widespread community transmission has triggered stringent …
impact on human health 1. Widespread community transmission has triggered stringent …
Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
CJ Gordon, EP Tchesnokov, RF Schinazi… - Journal of Biological …, 2021 - ASBMB
The RNA-dependent RNA polymerase of the severe acute respiratory syndrome coronavirus
2 is an important target in current drug development efforts for the treatment of coronavirus …
2 is an important target in current drug development efforts for the treatment of coronavirus …
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice
Coronaviruses (CoVs) traffic frequently between species resulting in novel disease
outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative …
outbreaks, most recently exemplified by the newly emerged SARS-CoV-2, the causative …
Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19
The COVID-19 pandemic needs no introduction at present. Only a few treatments are
available for this disease, including remdesivir and favipiravir. Accordingly, the …
available for this disease, including remdesivir and favipiravir. Accordingly, the …
[HTML][HTML] Molnupiravir: coding for catastrophe
Molnupiravir, a wide-spectrum antiviral that is currently in phase 2/3 clinical trials for the
treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as …
treatment of COVID-19, is proposed to inhibit viral replication by a mechanism known as …
Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19
Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …